D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
Sat0670 reducing the impact of the patient global on boolean remission criteria for rheumatoid arthritis
TL;DR: Increasing the PtGA cut-off to 15mm would provide highest consistency between Boolean with the Index based remission, while the integer cut-offs of 20mm would also allow the use on numerical rating scales, while keeping the patient perspective in the core of RA disease activity evaluation.
Journal ArticleDOI
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis
Maximilian Kugler,Mirjam Dellinger,Felix Kartnig,Lena Müller,Teresa Preglej,Leonhard X. Heinz,Elisabeth Simader,Lisa Göschl,Stephan E. Puchner,S Weiss,Lisa E. Shaw,Matthias Farlik,Wolfgang Weninger,Giulio Superti-Furga,Josef S Smolen,Guenter Steiner,Daniel Aletaha,Hans P. Kiener,Myles Lewis,Costantino Pitzalis,Anela Tosevska,Thomas Karonitsch,Michael Bonelli +22 more
TL;DR: In this article , the role of cytokine-activated FLS in orchestrating inflammation-associated synovial pathotypes was highlighted, providing novel insights into disease mechanisms of rheumatoid arthritis.
Posted ContentDOI
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination Stratagy
Daniela Sieghart,Claudia A. Hana,Caroline Dürrschmid,Leonhard X. Heinz,Helmuth Haslacher,Markus Zlesak,Giulia Piccini,Alessandro Manenti,Emanuele Montomoli,Anselm Jorda,Clemens Fedrizzi,Timothy Hasenoehrl,Andrej Zdravkovic,Karolina Anderle,Ursula Wiedermann,Susanne Drapalik,Helmut Steinbrecher,Felix Bergmann,Christa Firbas,Galateja Jordakieva,Barbara Wagner,Thomas Perkmann,Richard Crevenna,Markus Zeitlinger,Michael Bonelli,Daniel Aletaha,Helga Radner +26 more
Journal ArticleDOI
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment
Roberto Caporali,Daniel Aletaha,Raimon Sanmartí,Y. Takeuchi,Daojun Mo,Ewa Haładyj,Liliana Zaremba-Pechmann,Peter C. Taylor +7 more
TL;DR: Baricitinib (BARI) as mentioned in this paper is an oral selective Janus kinase 1/2 inhibitor, which is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA).
Proceedings ArticleDOI
Induction Of Sustained Remission In Early Inflammatory Arthritis With The Combination Of Infliximab Plus Methotrexate, Methotrexate Alone Or Placebo: The Dinora Trial
Tanja Stamm,Klaus P Machold,Daniel Aletaha,Farideh Alasti,Peter E. Lipsky,David S. Pisetsky,R. Landewe,D. van der Heijde,Alexandre Sepriano,Martin Aringer,Dimitrios T. Boumpas,G.-R. Burmester,Maurizio Cutolo,W Ebener,Winfried Graninger,Twj Huizinga,Georg Schett,Hendrik Schulze-Koops,PP Tak,F. C. Breedveld,Josef S Smolen +20 more
TL;DR: It is indicated that patients with early arthritis can benefit from induction therapy with anti-TNF plus MTX compared to MTX alone, suggesting the existence of a window of opportunity where intensive treatment can alter the disease evolution.